Exploring Collaboration between Pfizer and Sangamo Therapeutics
On January 3, 2018, Pfizer (PFE) and Sangamo Therapeutics (SGMO) announced a collaboration for developing a potential gene therapy. ALS (or Lou Gehrig’s disease) and FTLD are neurodegenerative disorders caused by mutations in the C9ORF72 gene.